Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 13/20 | 1.00 |
| ▸ | DDO | Q99489 | 7/20 | 0.61 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.44 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.41 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3361024 | 0.83 | DAO (0.71) | DAODDO | |
| SCHEMBL3395093 | 0.80 | DAO (0.67) | DAODDOGRIN2DGRIN3BGRIN1 | |
| SCHEMBL3432805 | 0.80 | DAO (0.67) | DAODDO | |
| SCHEMBL3433397 | 0.80 | DAO (0.67) | DAODDOGRIN2DGRIN3BGRIN1 | |
| SCHEMBL27288077 | 0.79 | DAO (0.65) | DAODDOGRIN2DGRIN3BGRIN1 | |
| SCHEMBL21435057 | 0.78 | DAO (0.63) | DAODDOGRIN2DGRIN3BGRIN1 | |
| SCHEMBL3422279 | 0.76 | DAO (0.61) | DAODDO | |
| SCHEMBL3363456 | 0.76 | DAO (1.00) | DAODDOKDM4E | |
| SCHEMBL3360150 | 0.75 | DAO (0.59) | DAODDOGRIN2DGRIN3BGRIN1 | |
| SCHEMBL9007825 | 0.75 | DAO (0.65) | DAOGRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9468669-B2 | Methods to treat dysregulated blood glucose disorders | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2016-10-18 | — | — | US | disclosed |
| US-9468669-B2 | Methods to treat dysregulated blood glucose disorders | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2016-10-18 | — | — | US | disclosed |
| US-20160228515-A1 | METHODS TO TREAT DYSREGULATED BLOOD GLUCOSE DISORDERS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2016-08-11 | — | — | US | disclosed |
| US-20160228515-A1 | METHODS TO TREAT DYSREGULATED BLOOD GLUCOSE DISORDERS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2016-08-11 | — | — | US | disclosed |
| US-9339482-B2 | Methods to treat dysregulated blood glucose disorders | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2016-05-17 | — | — | US | disclosed |
| US-9339482-B2 | Methods to treat dysregulated blood glucose disorders | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150150836-A1 | METHODS TO TREAT DYSREGULATED BLOOD GLUCOSE DISORDERS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2015-06-04 | — | — | US | disclosed |
| US-20150150836-A1 | METHODS TO TREAT DYSREGULATED BLOOD GLUCOSE DISORDERS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150150836-A1 | METHODS TO TREAT DYSREGULATED BLOOD GLUCOSE DISORDERS | SLC2A4, SLC2A2, SLC2A3 | DAO 3050/4885DDO 2128/4885GRIN2D 1892/4885 |
| US-20160228515-A1 | METHODS TO TREAT DYSREGULATED BLOOD GLUCOSE DISORDERS | SLC2A4, SLC2A2, SLC2A3 | DAO 3050/4885DDO 2128/4885GRIN2D 1892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.